A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Na ve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    High-risk Diffuse Large B-cell Lymphoma
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically-confirmed diagnosis of CD20-positive Diffuse Large B-Cell Lymphoma (DLBCL) 2. Able to swallow tablets

You may not be eligible for this study if the following are true:

  • 1. Receiving, or has the subject received, any other radiation or systemic anticancer treatment for lymphoma 2. Known central nervous system (CNS) involvement 3. A second primary malignancy (except adequately treated non-melanoma skin cancer)


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.